NASDAQ: RLAY - Relay Therapeutics, Inc.

Yield per half year: -50%
Sector: Healthcare

Share chart Relay Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Relay Therapeutics, Inc. работает как компания, специализирующаяся на прецизионных медицинских препаратах. Он занимается преобразованием процесса открытия лекарств с первоначальным акцентом на расширении терапевтических открытий малых молекул в целевой онкологии.

more details
Его продукты-кандидаты включают RLY-1971, пероральный низкомолекулярный ингибитор протеинтирозинфосфатазы, домен гомологии области 2, фосфатазы-2 (SHP2), который находится в фазе 1 исследований повышения дозы у пациентов с запущенными или метастатическими солидными опухолями; RLY-4008, пероральный низкомолекулярный селективный ингибитор рецептора 2 фактора роста фибробластов (FGFR2) для пациентов с развитыми солидными опухолями, имеющими онкогенные изменения FGFR2; и RLY-PI3K1047, ведущее соединение, которое нацелено на ассоциированные с раком мутантные варианты фосфоинозитид-3-киназы альфа. Компания была основана в 2015 году, ее штаб-квартира находится в Кембридже, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-07-16
ISIN US75943R1023
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.relaytx.com
Цена ао 4.45
Change price per day: 0% (4.45)
Change price per week: -2.63% (4.57)
Change price per month: -6.9% (4.78)
Change price per 3 month: -34.07% (6.75)
Change price per half year: -50% (8.9)
Change price per year: -59.55% (11)
Change price per 3 year: -78.68% (20.87)
Change price per 5 year: 0% (4.45)
Change price per 10 year: 0% (4.45)
Change price per year to date: +2.53% (4.34)
All parameters

Underestimation

Title Value Grade
P/S 55.08 1
P/BV 1.87 8
P/E 17.31 7
EV/EBITDA -3.46 0
Total: 4.88

Efficiency

Title Value Grade
ROA, % -40.52 0
ROE, % -45.47 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1405 10
Total: 8.2

Growth impulse

Title Value Grade
Yield Revenue, % -69.11 0
Yield Ebitda, % 360.78 10
Yield EPS, % -85.54 0
Total: 6
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
06.01.2025 06.01.2025 Rahmer Peter
See remarks		 Sale 4.45 73 763 16576 0 -0.02 link
03.01.2025 06.01.2025 Rahmer Peter
See remarks		 Sale 4.3 138 361 32177 0 -0.03 link
02.01.2025 06.01.2025 Rahmer Peter
See remarks		 Sale 4.15 133 447 32156 0 -0.03 link
27.12.2024 27.12.2024 THOMAS J CATINAZZO
Officer		 Purchase 4.42 20 182 4566 0 0 link
28.10.2024 30.10.2024 Adams Brian
Chief Legal Officer		 Sale 6.06 9 890 1632 0 0 link
28.10.2024 28.10.2024 THOMAS J CATINAZZO
Officer		 Purchase 6.06 30 936 5105 0 0 link
27.09.2024 01.10.2024 Adams Brian
Chief Legal Officer		 Sale 7.51 2 215 295 0 0 link
27.09.2024 01.10.2024 Bergstrom Donald A
President, R&D		 Sale 7.51 4 866 648 0 0 link
27.09.2024 01.10.2024 Catinazzo Thomas
Chief Financial Officer		 Sale 7.46 48 169 6457 0 -0.01 link
27.09.2024 01.10.2024 Rahmer Peter
See remarks		 Sale 7.51 1 840 245 0 0 link
10.06.2024 12.06.2024 Rubin Jami
Director		 Purchase 5.04 212 900 42242 0 0.04 link
29.04.2024 29.04.2024 Bergstrom Donald A
President, R&D		 Sale 6.38 17 137 2686 0 0 link
29.04.2024 29.04.2024 Catinazzo Thomas
Chief Financial Officer		 Sale 6.38 10 814 1695 0 0 link
29.04.2024 29.04.2024 Adams Brian
Chief Legal Officer		 Sale 6.38 10 355 1623 0 0 link
29.04.2024 29.04.2024 Rahmer Peter
See remarks		 Sale 6.38 8 581 1345 0 0 link
27.03.2024 29.03.2024 Adams Brian
Chief Legal Officer		 Sale 7.7 2 680 348 0 0 link
27.03.2024 29.03.2024 Rahmer Peter
See remarks		 Sale 7.7 2 295 298 0 0 link
27.03.2024 29.03.2024 Bergstrom Donald A
President, R&D		 Sale 7.7 5 891 765 0 0 link
27.03.2024 29.03.2024 Catinazzo Thomas
Chief Financial Officer		 Sale 7.7 2 680 348 0 0 link
27.06.2023 28.06.2023 Adams Brian
Chief Legal Officer		 Sale 12.12 3 563 294 0 0 link
27.06.2023 28.06.2023 Bergstrom Donald A
President, R&D		 Sale 12.12 7 842 647 0 0 link
27.12.2022 28.12.2022 Adams Brian
Chief Legal Officer		 Sale 14.49 4 275 295 0 0 link
27.12.2022 28.12.2022 Bergstrom Donald A
President, R&D		 Sale 14.49 14 200 980 0 0 link
27.12.2022 28.12.2022 Catinazzo Thomas
Chief Financial Officer		 Sale 14.49 6 448 445 0 0 link
13.10.2022 13.10.2022 Patel Sanjiv
President and CEO		 Sale 20.58 288 120 14000 0 -0.01 link
11.10.2022 13.10.2022 Patel Sanjiv
President and CEO		 Sale 21.36 299 040 14000 0 -0.01 link
27.09.2022 29.09.2022 Adams Brian
Chief Legal Officer		 Sale 22.73 6 683 294 0 0 link
27.09.2022 29.09.2022 Bergstrom Donald A
President, R&D		 Sale 22.73 22 184 976 0 0 link
08.09.2022 08.09.2022 Bergstrom Donald A
President, R&D		 Sale 30 750 000 25000 0 -0.02 link
08.09.2022 08.09.2022 Bergstrom Donald A
President, R&D		 Purchase 4.12 103 000 25000 0 0.02 link
08.09.2022 08.09.2022 Catinazzo Thomas
Chief Financial Officer		 Sale 30 787 710 26257 0 -0.02 link
01.09.2022 01.09.2022 Bergstrom Donald A
President, R&D		 Sale 23.07 186 867 8100 0 -0.01 link
01.09.2022 01.09.2022 Bergstrom Donald A
President, R&D		 Purchase 4.12 33 372 8100 0 0.01 link
24.08.2022 25.08.2022 Bergstrom Donald A
President, R&D		 Sale 25 375 000 15000 0 -0.01 link
24.08.2022 25.08.2022 Bergstrom Donald A
President, R&D		 Purchase 4.12 61 800 15000 0 0.01 link
24.03.2022 28.03.2022 Bergstrom Donald A
President, R&D		 Sale 30 300 000 10000 0 -0.01 link
24.03.2022 28.03.2022 Bergstrom Donald A
President, R&D		 Purchase 4.12 41 200 10000 0 0.01 link
24.03.2022 28.03.2022 Catinazzo Thomas
Chief Financial Officer		 Sale 30 398 580 13286 0 -0.01 link
24.03.2022 28.03.2022 Catinazzo Thomas
Chief Financial Officer		 Purchase 4.12 54 738 13286 0 0.01 link

Institutions Volume Share, %
SB INVESTMENT ADVISERS (UK) LTD 27904963 21.27
Vanguard Group Inc 10650387 8.12
Blackrock Inc. 9573423 7.3
Price (T.Rowe) Associates Inc 8581167 6.54
Casdin Capital, LLC 7387943 5.63
JP Morgan Chase & Company 6065595 4.62
Bellevue Group AG 5936082 4.53
State Street Corporation 4903578 3.74
BVF Inc. 3970045 3.03
ArrowMark Colorado Holdings LLC 3914246 2.98

ETF Share, % Profitability for 1 year, % Dividends, %
Range Cancer Therapeutics ETF 1.26796 47.24 0.11955
TrueShares Technology, AI & Deep Learning ETF 1.02465 24.67 0.0924
Virtus LifeSci Biotech Clinical Trials ETF 0.75923 63.04 0.33
Direxion Daily S&P Biotech Bull 3x Shares 0.12386 4067.92 0.25924
Avantis U.S Small Cap Equity ETF 0.11461 27.77 1.68271
Invesco Nasdaq Biotechnology ETF 0.1004 28.58 0.8565
Future Tech ETF 0.09706 426.34 0.8416
Principal Healthcare Innovators ETF 0.09706 618.5 0.8416
ProShares Ultra Nasdaq Biotechnology 0.06686 51.7 0.85651
JPMorgan BetaBuilders U.S. Small Cap Equity Fund 0.0475 24.75 1.59225
Vanguard Russell 2000 ETF 0.03 14.37 1.48801
iShares Morningstar Small-Cap Growth ETF 0.02976 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.02976 590.83 0.72598
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.02179 15.15 1.75869
Schwab U.S. Small-Cap ETF 0.02126 13.35 1.51433
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.01964 31.36 1.41955
ProShares UltraPro Russell2000 0.01612 89.82 1.47873
iShares Morningstar Small-Cap ETF 0.01505 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.01505 391.25 1.60498
Dimensional U.S. Targeted Value ETF 0.01459 26.01 1.93487
Fidelity MSCI Health Care Index ETF 0.01424 0.1657 1.46057
SPDR Portfolio MSCI Global Stock Market ETF 0.00525 15.66 2.19607
ProShares Hedge Replication ETF 0.00461 5.92 1.47892
Humankind US Stock ETF 0.00452 18.81 1.99919
Dimensional U.S. Core Equity 2 ETF 0.00299 30.76 1.47098
Dimensional US Core Equity Market ETF 0.00222 30.98 1.40618
Avantis U.S. Equity ETF 0.00174 20.45 1.59151
Schwab U.S. Broad Market ETF 0.00108 23.7 1.43354
Dimensional U.S. Equity ETF 0.00101 31.53 1.3557
iShares Russell 3000 ETF 0.00101 23.61 1.43482
Avantis Responsible U.S. Equity ETF 0.00001 26.78 1.45257
Vanguard ESG U.S. Stock ETF 0 23.74 1.26927
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Mr. Brian R. Adams J.D. Chief Legal Officer & Secretary 598.53k 1974 (51 year)
Mr. Thomas Catinazzo Chief Financial Officer 599.83k 1977 (48 years)
Mr. Peter Rahmer Chief Corporate Development Officer 570.52k
Mr. Alexis A. Borisy A.M. Co-Founder & Independent Chairman 85k 1972 (53 years)
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS CEO, President & Director 1.03M 1974 (51 year)
Dr. Mark Murcko Ph.D. Co-Founder & Director 50k 1960 (65 years)
Dr. Donald A. Bergstrom M.D., Ph.D. President of Research & Development 711.25k 1972 (53 years)
Ms. Dorothee Kern Ph.D. Founder
Dr. David Elliot Shaw Ph.D. Founder 1951 (74 years)
Mr. Matthew P. Jacobson Ph.D. Founder

Address: United States, Cambridge, MA , 399 Binney Street - open in Google maps, open in Yandex maps
Website: http://www.relaytx.com